DNA encoding C5A receptor antagonists having substantially no ag

Details DNA encoding C5A receptor antagonists having substantially no ag DNA encoding C5A receptor antagonists having substantially no ag

1995-06-05

1998-11-17

Walsh, Stephen

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

435 697, 435 701, 435 711, 4353201, 4352523, 43525411, 435325, 43525233, 530408, 536 234, 536 235, C12P 2100, C07K 14435, C12N 1512

Patent

active

058374990

ABSTRACT:
Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g., neutralize, the activity of the C5a receptor antagonist in vivo.

REFERENCES:
patent: 4620948 (1986-11-01), Builder et al.
patent: 4686100 (1987-08-01), Raffin et al.
patent: 4692511 (1987-09-01), Hahn
patent: 4772584 (1988-09-01), Cleary
patent: 4937189 (1990-06-01), Davidow et al.
patent: 5177190 (1993-01-01), Rollins et al.
patent: 5190922 (1993-03-01), Luly et al.
patent: 5614370 (1997-03-01), Konteatis et al.
Marston et al. Solubilization of Protein Assiegates. Methods in Enzymology. vol. 182, pp. 264-277. 1990.
Franke et al. Human C5A Anaplylatoxin: Gene Synthesis, Expression, and Recovery of Biologically Active Material From Escherichia coli. Methods in Enzymology vol. 162, pp. 653-668. 1988.
Canova-Davis et al. Chemical Heterogeneity as a Result of Hydroxylamine Cleavage of a Fusion Protein of Human Insulin-Like Growth Factor I. Biochemical Journal. vol. 285, pp. 207-213. 1992.
Kinoshita, Immunology Today 12:291-300 (1991).
Muller-Eberhard, Ann. Rev. Biochem 57:321-347 (1988).
Nilsson et al., J. Immunol. 114:815-822 (1975).
Hugli, CRC Crit. Rev. Immunol. 1:321-366 (1981).
Bautsch et al., Immunobiol. 185:41-52 (1992).
Fernandez, et al., J. Immunol. 120:109-115 (1978).
Bautsch et al., Biochem J. 288:261-266 (1992).
Haslett et al., J. Immunol. 142:3510-3517 (1989).
Mollison et al., Proc. Nat'l. Acad. Sci. USA 86:292-296 (1989).
Hammerschmidt, et al., Lancet 1:947-49 (1980).
Kawai et al., J. Med. Chem. 35:220-223 (1992).
Kawai et al., J. Med. Chem. 34:2068-2071 (1991).
Or et al., J. Med. Chem. 35:402-406 (1992).
Mollison et al., "C5a Structural Requirements for Neutryphil Receptor Interaction," in Progress in Inflammation Research and Therapy, Birkhaus Verlag, Basel (1991), pp. 17-21.
Oppermann et al., J. Immunol. 151(7):3785-3794 (1993).
Chenoweth et al., Mol. Immunol. 17:151-161 (1980).
Seligmann et al., Agents and Actions 21:375-378 (1987).
Fernandez et al., J. Biol. Chem. 253:6955-6964 (1978).
Mandecki et al., PROC. Nat'l. Acad. Sci. USA 82:3543-3547 (1985).
Carney et al., Protein Science 2:1391-1399 (1993).
Goff et al., Proc. Nat'l. Acad. Sci. USA 81:6647-6651 (1984).
Harris et al., J. Receptor Res. 11:115-128 (1991).
Rollins et al., J. Biol. Chem. 263:520-526 (1988).
Braunwalder et al., Mol. Immunol. 29(11):1319-1324 (1992).
Hensens et al., J. Antibiotics 44(2):249-254 (1991).
Greer et al., "Comparative Modeling of Proteins in the Complement Pathway"in Computer-Assisted Modeling of Receptor-Ligand Interactions: Theoretical Aspects and Applications to Drug Design: pp. 385-397 (1989).
Ayesh et al., J. Immunol. 144(8):3066-70 (1990).
Ember et al., J. Immunol. 148(10):3165-73 (1992).
Chenoweth et al., Proc. Natl. Acad. Sci. USA 75:3943-3947 (1978).
Gerard et al., Annu. Rev. Immunol. 12:775-808 (1994).

Affiliated with

Also associated with

Rating

DNA encoding C5A receptor antagonists having substantially no ag does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA encoding C5A receptor antagonists having substantially no ag, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding C5A receptor antagonists having substantially no ag will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-883188